Abdul Rafeh Naqash, MD

About Abdul Rafeh Naqash

Abdul Rafeh Naqash, MD received his medical degree at the Government Medical College Srinagar, Kashmir. He completed Internal Medicine residency training at the University of Buffalo/Catholic Health. Subsequently, Dr. Naqash completed his sub-specialty clinical training in Hematology/Oncology at East Carolina University, Greenville, NC and a early phase clinical trial fellowship at the National Cancer Inst, Bethesda in the developmental therapeutics clinic. As part of the TSET phase 1 program at Stephenson Cancer Center, Dr. Naqash is focusing his interest in drug development and incorporating a genomically driven approach to early phase clinical trials. He is also interested in Lung Cancer, immunotherapy biomarkers , understanding resistance patters to Immunotherapy and immune toxicities. Dr. Naqash has led and collaborated extensively with national and international leaders in the field of immunotherapy. Some of this work has been published in high impact journals such as Journal of Clinical Oncology, JAMA Oncology, Journal of Immunotherapy of Cancer, Clinical Cancer Research among others. Dr. Naqash has been the recipient of several coveted nationally recognized awards, including The ASCO-SITC merit awards, The ASCO merit awards, the ASCO- Young Investigator Award and The NCI Directors Award among several others. Dr. Naqash is an executive member of the SITC Early Career Scientist Committee, the ASCO Trainee and Early Career Council, IASLC Career Development Committee where he is actively involved in working towards developing educational initiatives for early-career investigators. Dr Naqash also serves as the social media editor for JCO Precision Oncology and is a member of the ASCO Social Media Working group developing strategies to facilitate outreach for ASCO journals and ASCO meetings on social media platforms.

Outside of work, Dr. Naqash enjoys traveling, hiking and spending time with his family.

• Early Phase clinical trials in solid tumors
• Drug development
• Immunotherapy biomarkers
• Immunotherapy resistance
• Immune related adverse events
• Lung cancer